OpenLB
Open Library of Bioscience
Advanced Search
Wiener medizinische Wochenschrift (1946)
May, 2017;167 (7-8): 160-168.

Modulation of gastrointestinal motility beyond metoclopramide and domperidone : Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders.

Ahmed Madisch, Bettina R Vinson, Heba Abdel-Aziz, Olaf Kelber, Karen Nieber, Karin Kraft, Martin Storr
Author Information
  1. Ahmed Madisch: Gastroenterologie, Interventionelle Endoskopie, Diabetologie, KRH Klinikum Siloah, Hannover, Germany.
  2. Bettina R Vinson: Medical and Clinical Affairs Phytomedicines, Innovation and Development, Phytomedicines Supply and Development Center, Bayer Consumer Health, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany.
  3. Heba Abdel-Aziz: Medical and Clinical Affairs Phytomedicines, Innovation and Development, Phytomedicines Supply and Development Center, Bayer Consumer Health, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany.
  4. Olaf Kelber: Scientific Strategy Phytomedicines, Innovation and Development, Phytomedicines Supply and Development Center, Bayer Consumer Health, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany.
  5. Karen Nieber: Institut für Pharmazie, Universität Leipzig, Leipzig, Germany.
  6. Karin Kraft: Lehrstuhl für Naturheilkunde, Zentrum für Innere Medizin, Universitätsmedizin Rostock, Rostock, Germany.
  7. Martin Storr: Zentrum für Endoskopie, Oßwaldstraße 1, 82319, Starnberg, Germany. gidoc@gmx.com.
PMID: 28424994 DOI: 10.1007/s10354-017-0557-3

Abstract

The prokinetic cisapride, an important therapeutic option in functional gastrointestinal (GI) disorders, was withdrawn from the market 15 years ago due to rare severe side effects. Likewise in 2014, the use of metoclopramide (MCP) and domperidone in functional GI disorders (FGID) was restricted, consequently leaving a therapeutic gap in clinical practice. A systematic review revealed that the herbal medicinal product (HMP) STW 5 presents a therapeutic option equivalent to MCP and cisapride. STW 5 is the only HMP for which efficacy has been shown in randomized controlled clinical trials (RCTs) in functional dyspepsia and irritable bowel syndrome, based on its multitarget effect on numerous etiological factors. Due to an outstanding favorable safety profile, STW 5 allows an effective and safe use in FGID without a limitation of the duration of the treatment.

Keywords

Evidence-based medicine Functional dyspepsia Herbal medicinal product Irritable bowel syndrome Prokinetic drugs

References

  1. Arzneimittelforschung. 1999 Nov;49(11):925-32 [PMID: 10604046]
  2. Curr Opin Pharmacol. 2011 Dec;11(6):604-11 [PMID: 21996284]
  3. Arzneimittelforschung. 1991 Jun;41(6):631-4 [PMID: 1930352]
  4. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 May;28(5):454-6 [PMID: 18672777]
  5. Phytomedicine. 2006;13 Suppl 5:90-9 [PMID: 16765572]
  6. Phytomedicine. 2006;13 Suppl 5:12-9 [PMID: 16857355]
  7. Hepatogastroenterology. 2012 Jan-Feb;59(113):62-6 [PMID: 22260823]
  8. Aliment Pharmacol Ther. 2004 Feb 1;19(3):271-9 [PMID: 14984373]
  9. Z Gastroenterol. 2007 Oct;45(10):1041-8 [PMID: 17924300]
  10. Am J Gastroenterol. 2007 Jun;102(6):1276-83 [PMID: 17378904]
  11. Z Gastroenterol. 2002 Jun;40(6):401-8 [PMID: 12055663]
  12. Wien Med Wochenschr. 2013 Feb;163(3-4):65-72 [PMID: 23263639]
  13. Scand J Gastroenterol. 1994 Jan;29(1):33-7 [PMID: 8128175]
  14. J Pharmacol Sci. 2010;113(2):134-42 [PMID: 20484868]
  15. Am J Gastroenterol. 2003 Nov;98(11):2454-9 [PMID: 14638348]
  16. Int J Colorectal Dis. 2012 Nov;27(11):1445-53 [PMID: 22562255]
  17. Eur J Pharmacol. 1985 Jan 22;108(2):105-12 [PMID: 3979439]
  18. Chin J Integr Med. 2005 Mar;11(1):27-30 [PMID: 15975303]
  19. Phytomedicine. 2009 Mar;16(2-3):161-71 [PMID: 19196500]
  20. Phytomedicine. 2006;13 Suppl 5:67-74 [PMID: 16978852]
  21. Phytomedicine. 2006;13 Suppl 5:114-21 [PMID: 16978851]
  22. Control Clin Trials. 1996 Feb;17(1):1-12 [PMID: 8721797]
  23. Aliment Pharmacol Ther. 2004 Dec;20(11-12):1279-87 [PMID: 15606389]
  24. Phytomedicine. 2006;13 Suppl 5:75-9 [PMID: 16709451]
  25. Aliment Pharmacol Ther. 2005 Aug 15;22(4):357-63 [PMID: 16098003]
  26. J Pediatr Gastroenterol Nutr. 1986 Jan;5(1):134-7 [PMID: 2868086]

MeSH Term

Domperidone
Gastrointestinal Diseases
Gastrointestinal Motility
Humans
Irritable Bowel Syndrome
Metoclopramide
Phytotherapy
Plant Extracts
Randomized Controlled Trials as Topic

Chemicals

Plant Extracts
iberogast
Domperidone
Metoclopramide
Comparative Study Journal Article Review Systematic Review
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0functionalgastrointestinaldisordersclinicalSTW 5cisaprideoptionGIusemetoclopramideMCPdomperidoneFGIDa therapeuticmedicinalproductHMPdyspepsiabowelsyndromeprokineticimportanttherapeuticwithdrawnmarket15 yearsagoduerareseveresideeffectsLikewise2014restrictedconsequentlyleavinggappracticeA systematicreviewrevealedherbalpresentsequivalentefficacyshownrandomizedcontrolledtrialsRCTsirritablebasedmultitargeteffectnumerousetiologicalfactorsDueoutstandingfavorablesafetyprofileallowseffectivesafewithouta limitationdurationtreatmentModulationmotilitybeyond:PharmacologicalevidencephytotherapyEvidence-basedmedicineFunctionalHerbalIrritableProkineticdrugs

Similar Articles

Cited By